HUP9801140A2 - Antifungal composition - Google Patents
Antifungal compositionInfo
- Publication number
- HUP9801140A2 HUP9801140A2 HU9801140A HUP9801140A HUP9801140A2 HU P9801140 A2 HUP9801140 A2 HU P9801140A2 HU 9801140 A HU9801140 A HU 9801140A HU P9801140 A HUP9801140 A HU P9801140A HU P9801140 A2 HUP9801140 A2 HU P9801140A2
- Authority
- HU
- Hungary
- Prior art keywords
- stone
- infusions
- fungal
- treatment
- azole
- Prior art date
Links
- 239000012871 anti-fungal composition Substances 0.000 title 1
- 239000004575 stone Substances 0.000 abstract 5
- 238000001802 infusion Methods 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 208000031888 Mycoses Diseases 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 230000000507 anthelmentic effect Effects 0.000 abstract 2
- 241000193738 Bacillus anthracis Species 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 208000022338 anthrax infection Diseases 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 150000007980 azole derivatives Chemical class 0.000 abstract 1
- 239000002316 fumigant Substances 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 abstract 1
- 229960002722 terbinafine Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A találmány gőmbaellenes hatású kőmpőzíciókra, azők alkalmazására,ilyen kőmpőzíciók előállítására szőlgáló eljárásra, valamintgőmbafertőzések kezelésére alkalmas eljárásra vőnatőzik. A találmányszerinti, azőlőkkal szemben ellenállóképes élesztőgőmbatörzsek általembereken előidézett gőmbás fertőzések kezelésére alkalmas,gőmbaellenes hatású kőmpőzíciók terbinafint és 14a-metil-demetiláz-inhibitőr- ként azőlt tartalmaznak. Az azőlszármazék(ők)kal szemben ellenállóképessé vált gőmbatörzsekáltal őkőzőtt azőlrezisztens gőmbafertőzéseket úgy kezelik a találmányszerinti módszerrel, hőgy a találmány szerinti, gőmbaellenes hatásúkőmpőzíciókat a gyógyhatás eléréséhez megfelelő mennyiségben jűttatjákbe az ilyen kezelésre rászőrűló betegek szervezetébe. A találmány szerinti kőmpőzíciók előnye, hőgy alkalmazás esetén azazőlszármazék(ők)kal szemben rezisztenssé vált gőmbatörzsek általelőidézett gőmbás megbetegedések is kezelhetők. ŕThe invention relates to stone infusions with anthelmintic effect, to their application, to a process for the production of such stone infusions, and to a process suitable for the treatment of anthelmintic infections. According to the invention, the anti-fungal stone infusions suitable for the treatment of fungal infections caused by yeast fungi strains resistant to fungi contain terbinafine and 14a-methyldemethylase inhibitor, fumigant. Azole-resistant anthrax infections caused by anthrax strains that have become resistant to the azole derivative(s) are treated with the method according to the invention, in which the anti-azole stone compositions according to the invention are injected into the body of patients requiring such treatment in an amount sufficient to achieve a therapeutic effect. The advantage of the stone infusions according to the invention is that fungal diseases caused by fungal strains that have become resistant to the herbal derivative(s) can also be treated when applied with heat. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9509631.9A GB9509631D0 (en) | 1995-05-12 | 1995-05-12 | Antifungal combination |
PCT/EP1996/002022 WO1996035423A1 (en) | 1995-05-12 | 1996-05-10 | Antifungal composition |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP9801140A2 true HUP9801140A2 (en) | 1999-01-28 |
HUP9801140A3 HUP9801140A3 (en) | 2000-07-28 |
HU224920B1 HU224920B1 (en) | 2006-04-28 |
Family
ID=10774361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9801140A HU224920B1 (en) | 1995-05-12 | 1996-05-10 | Use of an antifungal composition |
Country Status (26)
Country | Link |
---|---|
US (1) | US5985906A (en) |
EP (1) | EP0824350B1 (en) |
JP (1) | JPH11504931A (en) |
KR (1) | KR100443535B1 (en) |
CN (1) | CN1100539C (en) |
AT (1) | ATE246504T1 (en) |
AU (1) | AU712914B2 (en) |
CA (1) | CA2219651C (en) |
CY (1) | CY2496B1 (en) |
CZ (1) | CZ291144B6 (en) |
DE (1) | DE69629367T2 (en) |
DK (1) | DK0824350T3 (en) |
ES (1) | ES2205042T3 (en) |
FI (1) | FI120079B (en) |
GB (1) | GB9509631D0 (en) |
HK (1) | HK1016064A1 (en) |
HU (1) | HU224920B1 (en) |
IL (2) | IL118219A (en) |
MX (1) | MX9708699A (en) |
NO (1) | NO317030B1 (en) |
PL (1) | PL322749A1 (en) |
PT (1) | PT824350E (en) |
SK (1) | SK150797A3 (en) |
TW (1) | TW464492B (en) |
WO (1) | WO1996035423A1 (en) |
ZA (1) | ZA963754B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
AU783158B2 (en) * | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
GB0001315D0 (en) * | 2000-01-20 | 2000-03-08 | Novartis Ag | Organic compounds |
GB0003932D0 (en) * | 2000-02-18 | 2000-04-12 | Novartis Ag | Pharmaceutical compositions |
US6673373B2 (en) | 2001-02-01 | 2004-01-06 | Carlsbad Technology Inc. | Antifungal formulation and the methods for manufacturing and using the same |
US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
US20040225077A1 (en) | 2002-12-30 | 2004-11-11 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
ATE474591T1 (en) | 2003-12-08 | 2010-08-15 | Cpex Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR INSULIN TREATMENT |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
ES2368078T3 (en) | 2005-04-07 | 2011-11-14 | Toyama Chemical Co., Ltd. | PHARMACEUTICAL COMPOSITION AND METHOD USED BY AN ANTIFUNGICAL AGENT IN COMBINATION. |
PT2070536E (en) | 2006-10-06 | 2012-03-06 | Toyama Chemical Co Ltd | Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent |
JP2010512343A (en) * | 2006-12-08 | 2010-04-22 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | Preparation and utility of substituted allylamines |
CA2711765A1 (en) | 2008-01-11 | 2009-07-16 | Massachusetts Eye & Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
EP3008192B1 (en) | 2013-06-11 | 2019-07-17 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
US4218458A (en) * | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
GB2099818A (en) * | 1981-06-06 | 1982-12-15 | Pfizer Ltd | Triazoles |
US4782059A (en) * | 1986-09-29 | 1988-11-01 | Merck & Co., Inc. | Method of controlling mycotic infections and compositions therefor |
JP2581707B2 (en) * | 1987-10-02 | 1997-02-12 | 科研製薬株式会社 | Antifungal composition |
CA2016738A1 (en) * | 1989-06-08 | 1990-12-08 | Philippe Guerry | Substituted aminoalkylbenzene derivatives |
JPH0338521A (en) * | 1989-07-05 | 1991-02-19 | Maruho Kk | Antifungal composition |
JPH0338522A (en) * | 1989-07-05 | 1991-02-19 | Maruho Kk | Antifungal composition |
CA2020888A1 (en) * | 1989-07-27 | 1991-01-28 | Philippe Guerry | Substituted aminoalkoxybenzene derivatives |
US5214046A (en) * | 1989-07-27 | 1993-05-25 | Hoffmann-La Roche Inc. | Substituted aminoalkoxybenzene anti-fungicidal compositions and use |
CA2044533A1 (en) * | 1990-06-29 | 1991-12-30 | Philippe Guerry | Substituted aminoalkylbiphenyl derivatives |
US5696164A (en) * | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
JP3038521U (en) | 1996-12-05 | 1997-06-20 | 啓次 小峰 | Water-soluble fiber stick-like absorbent material for temporary excrement holder |
JP3038522U (en) | 1996-12-05 | 1997-06-20 | 秀俊 筬 | Cardboard box potpourri |
-
1995
- 1995-05-12 GB GBGB9509631.9A patent/GB9509631D0/en active Pending
-
1996
- 1996-05-10 EP EP96919769A patent/EP0824350B1/en not_active Expired - Lifetime
- 1996-05-10 HU HU9801140A patent/HU224920B1/en not_active IP Right Cessation
- 1996-05-10 PT PT96919769T patent/PT824350E/en unknown
- 1996-05-10 CN CN96193853A patent/CN1100539C/en not_active Expired - Fee Related
- 1996-05-10 TW TW085105532A patent/TW464492B/en active
- 1996-05-10 SK SK1507-97A patent/SK150797A3/en unknown
- 1996-05-10 IL IL11821996A patent/IL118219A/en not_active IP Right Cessation
- 1996-05-10 WO PCT/EP1996/002022 patent/WO1996035423A1/en not_active Application Discontinuation
- 1996-05-10 ZA ZA9603754A patent/ZA963754B/en unknown
- 1996-05-10 PL PL96322749A patent/PL322749A1/en unknown
- 1996-05-10 DE DE69629367T patent/DE69629367T2/en not_active Expired - Lifetime
- 1996-05-10 US US08/952,288 patent/US5985906A/en not_active Expired - Fee Related
- 1996-05-10 AU AU58183/96A patent/AU712914B2/en not_active Ceased
- 1996-05-10 JP JP8533792A patent/JPH11504931A/en active Pending
- 1996-05-10 IL IL11821995A patent/IL118219A0/en unknown
- 1996-05-10 ES ES96919769T patent/ES2205042T3/en not_active Expired - Lifetime
- 1996-05-10 CZ CZ19973547A patent/CZ291144B6/en not_active IP Right Cessation
- 1996-05-10 CA CA002219651A patent/CA2219651C/en not_active Expired - Fee Related
- 1996-05-10 KR KR1019970708050A patent/KR100443535B1/en not_active IP Right Cessation
- 1996-05-10 DK DK96919769T patent/DK0824350T3/en active
- 1996-05-10 MX MX9708699A patent/MX9708699A/en not_active IP Right Cessation
- 1996-05-10 AT AT96919769T patent/ATE246504T1/en not_active IP Right Cessation
-
1997
- 1997-09-26 FI FI973812A patent/FI120079B/en not_active IP Right Cessation
- 1997-11-07 NO NO19975134A patent/NO317030B1/en not_active IP Right Cessation
-
1998
- 1998-12-10 HK HK98113058A patent/HK1016064A1/en not_active IP Right Cessation
-
2004
- 2004-12-27 CY CY0400091A patent/CY2496B1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9801140A2 (en) | Antifungal composition | |
WO2002043652A3 (en) | Anti-proliferative drugs | |
HUP0302114A2 (en) | Liquis pharmaceutical composition comprising erythropoietin protein, method for its preparation and its use | |
NO20060307L (en) | Use of the quinoazoline derivative ZD6474 in combination with platinum compounds and possibly ionizing radiation in the treatment of diseases associated with angiogenesis and / or ocular vascular permeability | |
TR200102809T2 (en) | Bacillus pumilus line for control of plant diseases | |
AR109103A1 (en) | TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT | |
WO2009020643A3 (en) | Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue | |
HK1083196A1 (en) | Topical compositions having a natural ingredient and method of use | |
NO20045038L (en) | Combination of a beta-2 adrenoceptor agonist and an amino sugar and their use in the treatment of immunomodulatory diseases | |
AU2001265151A1 (en) | Method of stimulating hair growth | |
BRPI0409865A (en) | intravenous injection of non-neurotoxic plasminogen activators for stroke attack treatment | |
MD1651G2 (en) | Fungi strains Nectria pityrodes Montagne possessing fungicidal properties and process for screening thereof, biofungicide, biofungicidal composition and method of fungicidal inhibition | |
ZA202104960B (en) | Methods of treating pain with a thiazoline anti-hyperalgesic | |
HK1087328A1 (en) | Therapeutic composition for autoimmune conditions | |
ATE488226T1 (en) | MAHONIA AQUIFOLIUM EXTRACT, EXTRACTION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
MA27474A1 (en) | VACCINE | |
WO1999065475A3 (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
WO2007008904A3 (en) | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections | |
ATE502637T1 (en) | MEDICATIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE USING AN ANTICHOLINERGIC | |
WO2019232203A3 (en) | Methods and compositions to alleviate vascular permeability | |
ATE157255T1 (en) | COMPOSITION FOR THE COMBAT OF DERMATOMYCOSIS AND THEIR PATHOGENS AS WELL AS SWEATING AND BODY ODOR | |
Zaias et al. | Superficial mycoses: treatment with a new, broad-spectrum antifungal agent: 1% clotrimazole solution | |
MX2023002776A (en) | Glycoconjugates and medical uses thereof. | |
WO2003059262A3 (en) | Method and composition for treating and preventing hiv infection and aids | |
MX2021015796A (en) | Compositions and methods for treating eye diseases. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU Representative=s name: DERZSI KATALIN, S.B.G. & K. BUDAPESTI NEMZETKO, HU |
|
FH92 | Termination of representative |
Representative=s name: DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU |
|
MM4A | Lapse of definitive patent protection due to non-payment of fees |